TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This early phase I trial studies the side effects and feasibility of total body irradiation
using intensity modulation radiation therapy (IMRT) when given in combination with
cyclophosphamide prior to stem cell transplant to treat severe systemic sclerosis. IMRT
delivers total body radiation therapy more precisely and may reduce radiation exposure to
sensitive normal organs. Giving chemotherapy, such as cyclophosphamide, and total body
irradiation before a donor stem cell transplant helps kill cancer cells in the body and helps
make room in the bone marrow for new blood-forming cells (stem cells) to grow. Giving IMRT
and cyclophosphamide prior to stem cell transplant may work better in treating severe
systemic sclerosis and reduce radiation doses to lung and kidneys compared to
cyclophosphamide alone.